Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates

Clinical Microbiology and Infection

Volumn 18, Issue 8, 2012, Pages

  Erikstrup, L T ^a,b   Danielsen, T K L ^c   Hall, V ^d   Olsen, K E P ^e   Kristensen, B ^e   Kahlmeter, G ^f   Fuursted, K ^a   Justesen, U S ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e STATENS SERUM INSTITUT   (Denmark)

^f CENTRAL HOSPITAL   (Sweden)

Author keywords

Breakpoint; Clostridium difficile; Disk diffusion; Gradient test; Reduced susceptibility; Susceptibility testing

Indexed keywords

METRONIDAZOLE; MOXIFLOXACIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; DENMARK; DIARRHEA; DISK DIFFUSION; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

BRUCELLA; CLOSTRIDIUM DIFFICILE;

EID: 84864065953     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03907.x     Document Type: Article

References (29)

1. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut 2008; 57: 850-860.
2. Bartlett JG, Perl TM. The new Clostridium difficile - what does it mean? N Engl J Med 2005; 353: 2503-2505.
3. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307.
4. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46 (suppl): 32-42.
5. Brazier JS, Fawley W, Freeman J, Wilcox MH. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001; 48: 741-742.
6. Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999; 34: 1-6.
7. Peláez T, Alcalá L, Alonso R, Rodríguez-Créixems M, García-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46: 1647-1650.
8. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-1052.
9. Mutlu E, Wroe AJ, Sanchez-Hurtado K, Brazier JS, Poxton IR. Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J Med Microbiol 2007; 56: 921-929.
10. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Seventh Edition. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI), CLSI document M11-A7; 2007.
11. Citron DM, Ostovari MI, Karlsson A, Goldstein EJ. Evaluation of the E test for susceptibility testing of anaerobic bacteria. J Clin Microbiol 1991; 29: 2197-2203.
12. Rosenblatt JE, Gustafson DR. Evaluation of the Etest for susceptibility testing of anaerobic bacteria. Diagn Microbiol Infect Dis 1995; 22: 279-284.
13. Huhulescu S, Sagel U, Fiedler A et al. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile. J Med Microbiol 2011; 60: 1206-1212.
14. Levett PN. Antimicrobial susceptibility of Clostridium difficile determined by disc diffusion and breakpoint methods. J Antimicrob Chemother 1988; 22: 167-173.
15. Hoegh AM, Nielsen JB, Lester A, Friis-Møller A, Schønning K. A multiplex, internally controlled real-time PCR assay for detection of toxigenic Clostridium difficile and identification of hypervirulent strain 027/ST-1. Eur J Clin Microbiol Infect Dis 2011; 31: 1073-1079. [Epub ahead of print].
16. O'Neill GL, Ogunsola FT, Brazier JS, Duerden BI. Modification of a PCR Ribotyping Method for Application as a Routine Typing Scheme for Clostridium difficile. Anaerobe 1996; 2: 205-209.
17. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461-463.
18. Metzler CM, DeHaan RM. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis 1974; 130: 588-594.
19. Clinical and Laboratory Standards Institute (CLSI). Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline-Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI), CLSI document M23-A3; 2008.
20. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20: 391-408.
21. Lorian V. Antibiotics in Laboratory Medicine, 5th edn. Philadelphia: Lippincott Williams and Wilkins, 2005.
22. Kronvall G, Giske CG, Kahlmeter G. Setting interpretive breakpoints for antimicrobial susceptibility testing using disk diffusion. Int J Antimicrob Agents 2011; 38: 281-290.
23. Poilane I, Cruaud P, Torlotin JC, Collignon A. Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile. Clin Microbiol Infect 2000; 6: 155-156.
24. Kuijper EJ, Wilcox MH. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 2008; 47: 63-65.
25. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-1590.
26. Huang H, Nord CE. Can metronidazole still be used for treatment of Clostridium difficile infections? Curr Infect Dis Rep 2009; 11: 3-6.
27. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-1172.
28. Freeman J, Bauer MP, Baines SD et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-549.
29. Baird DR. Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile. J Antimicrob Chemother 1989; 23: 167-169.